Improving awareness, identification, and management of meibomian gland dysfunction

Ophthalmology. 2012 Oct;119(10 Suppl):S1-12. doi: 10.1016/j.ophtha.2012.06.064.

Abstract

Ocular surface disorder--and dry eye, in particular--is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers and clinicians have lacked a global consensus on the definition of MGD, its epidemiology, pathophysiology, and management. Various systemic diseases and medications have been associated with the progression of both dry eye and MGD, as have several ocular disorders beyond those directly affecting the surface. It is in the best interest of patients for clinicians to be able to better identify and diagnose MGD, differentiating it from other ocular surface disorders, and to recognize the effects of MGD on the ocular surface, and thus initiate appropriate therapy. This CME activity provides expert insight into the Tear Film and Ocular Surface Society's International Workshop on MGD consensus report, offering practical application of its findings to better manage MGD patient care, particularly for those patients facing or undergoing ocular surgery.

Publication types

  • Case Reports
  • Consensus Development Conference
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cyclosporine / administration & dosage
  • Dry Eye Syndromes / diagnosis*
  • Dry Eye Syndromes / metabolism
  • Eyelid Diseases / classification
  • Eyelid Diseases / diagnosis*
  • Eyelid Diseases / metabolism
  • Female
  • Humans
  • Keratomileusis, Laser In Situ
  • Lacrimal Apparatus Diseases / diagnosis*
  • Lacrimal Apparatus Diseases / metabolism
  • Male
  • Meibomian Glands / pathology*
  • Middle Aged
  • Ophthalmic Solutions / administration & dosage
  • Tears / metabolism
  • Visual Acuity

Substances

  • Ophthalmic Solutions
  • Cyclosporine